Area of research
Genetics · Hematology
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, and Kruppel-like factors research.
A single <i>JAK2</i>-V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non-conditioned recipient mice.
Identification of Hepatic-like EPO as a Cause of Polycythemia.
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.
JAK2/JAK2V617F heterodimers activate STAT1 and AhR to promote thrombocytosis.
Single <i>JAK2</i> -V617F hematopoietic stem cells can initiate MPN in transplantations into non-conditioned recipient mice
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.
Nuclear and cytosolic fractions of SOX2 synergize as transcriptional and translational co-regulators of cell fate.
Genetic basis and molecular profiling in myeloproliferative neoplasms.
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches.
Remodeling of metabolism and inflammation by exercise ameliorates tumor-associated anemia.
Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion.
The EHA Research Roadmap: Malignant Myeloid Diseases.
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents.
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation.
Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia.
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages.
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation.